Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted Therapies

Article

The nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting.

Madelaine Kuiper, MSN, NP, from UCLA Health, discussed the progression of HER2-positive breast cancer treatment at the San Antonio Breast Cancer Symposium, held December 10-14, in San Antonio, Texas.

Transcription:
You know look, honestly, from determining when Dr. Slamon first developed HER2 notification or amplification and then developing trastuzumab (Herceptin) to manage this disease, I mean it’s changed rapidly. I have to say, I do remember in the 80s when he was working on this stuff and when we were actually treating patients once approved, but even in the last, gosh, you know the last 6 years that I’ve been working with breast particularly, is the rapid development of HER2 targeted therapies, you know, with the development of trastuzumab emtansine (T-DM1) and then pertuzumab (Perjeta) and then the oral tucatinib, and now some of the later stuff with DS-8201 (trasuzumab deruxtecan), I mean it’s just amazing how many drugs are looking very positive in this setting and expanding treatment options for patients definitely.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content